WASHINGTON TRUST Co reduced its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 2.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 101,414 shares of the medical research company's stock after selling 2,540 shares during the quarter. WASHINGTON TRUST Co owned approximately 0.06% of IQVIA worth $19,929,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. FMR LLC increased its position in IQVIA by 38.7% during the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company's stock worth $684,213,000 after purchasing an additional 804,963 shares in the last quarter. B. Metzler seel. Sohn & Co. Holding AG acquired a new position in shares of IQVIA in the third quarter valued at approximately $147,683,000. JPMorgan Chase & Co. lifted its stake in shares of IQVIA by 46.2% during the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company's stock valued at $437,378,000 after buying an additional 583,396 shares during the period. Nordea Investment Management AB boosted its position in IQVIA by 47.4% during the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company's stock worth $277,908,000 after acquiring an additional 452,029 shares during the last quarter. Finally, KBC Group NV grew its stake in IQVIA by 68.5% in the 4th quarter. KBC Group NV now owns 616,299 shares of the medical research company's stock worth $121,109,000 after acquiring an additional 250,458 shares during the period. Institutional investors and hedge funds own 89.62% of the company's stock.
Wall Street Analyst Weigh In
A number of brokerages have weighed in on IQV. BTIG Research lowered IQVIA from a "buy" rating to a "neutral" rating in a research note on Monday, February 3rd. Stephens assumed coverage on IQVIA in a research report on Friday, December 20th. They set an "overweight" rating and a $250.00 target price on the stock. Deutsche Bank Aktiengesellschaft lowered their price target on IQVIA from $270.00 to $265.00 and set a "buy" rating for the company in a report on Friday, November 1st. Robert W. Baird decreased their target price on shares of IQVIA from $212.00 to $210.00 and set a "neutral" rating on the stock in a research report on Tuesday, January 21st. Finally, UBS Group dropped their price target on shares of IQVIA from $260.00 to $255.00 and set a "buy" rating for the company in a research report on Friday, February 7th. Four analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $251.22.
View Our Latest Research Report on IQVIA
IQVIA Stock Up 1.8 %
IQV stock traded up $3.39 during midday trading on Wednesday, hitting $196.54. 1,702,945 shares of the company's stock were exchanged, compared to its average volume of 1,412,729. The stock has a market capitalization of $34.61 billion, a price-to-earnings ratio of 26.21, a price-to-earnings-growth ratio of 1.98 and a beta of 1.48. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. The firm has a 50 day moving average price of $199.95 and a 200-day moving average price of $217.09. IQVIA Holdings Inc. has a 12-month low of $187.62 and a 12-month high of $261.73.
IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, analysts anticipate that IQVIA Holdings Inc. will post 10.86 EPS for the current year.
Insider Buying and Selling
In related news, Director John G. Danhakl bought 1,275 shares of the company's stock in a transaction on Tuesday, December 3rd. The shares were purchased at an average cost of $200.58 per share, with a total value of $255,739.50. Following the completion of the transaction, the director now directly owns 1,275 shares of the company's stock, valued at approximately $255,739.50. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 1.60% of the company's stock.
About IQVIA
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Further Reading
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
